文献速递慢性肾脏病血液净化与透析水电解质与酸碱

新型磷结合剂VS-505(AP301)在维持性血透患者中的耐受性、安全性和疗效:2期剂量递增和剂量范围研究

Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该2期研究评估口服VS-505(金合欢纤维-铁聚合物)在维持性血透合并高磷血症患者中的耐受性、安全性和疗效。研究分两部分:剂量递增和随机开放固定剂量对照。结果显示VS-505耐受良好,最常见不良事件为胃肠道反应(粪便变色56%,腹泻15%),血清磷显著且剂量依赖性下降。

要点

  • VS-505耐受良好,常见不良事件为粪便变色和腹泻,多可自行缓解
  • 剂量递增后血清磷平均下降2.0 mg/dL(95%CI -2.7,-1.4)
  • 固定剂量4.50和6.75 g/日及司维拉姆4.80 g/日均显著降磷,呈剂量依赖性

核心结论

  • VS-505在维持性血透高磷血症患者中耐受良好,安全性可控,能有效且剂量依赖性降低血清磷。

研究设计与样本

  • 2期两部分研究:第一部分为剂量递增(VS-505 2.25、4.50、9.00 g/日各2周),第二部分为随机开放固定剂量(VS-505 1.50、2.25、4.50、6.75 g/日或司维拉姆4.80 g/日,6周)。
  • 共入组158例患者(第一部分25例,第二部分133例),其中130例接受VS-505。

主要发现

  • 最常见不良事件为胃肠道疾病,主要是粪便变色(56%)和腹泻(15%),多发生在治疗第1-2周。
  • 大多数胃肠道不良事件无需干预自行缓解,无严重不良事件。
  • 第一部分剂量递增后血清磷显著改善,平均变化-2.0 mg/dL(95%CI -2.7,-1.4)。
  • 第二部分各VS-505剂量组血清磷均显著且剂量依赖性改善,4.50和6.75 g/日组及司维拉姆4.80 g/日组平均变化分别为-1.6(-2.2,-1.0)、-1.8(-2.4,-1.2)和-1.4(-2.2,-0.5)mg/dL。
  • 两部分中血清磷下降均在VS-505开始后1周内出现,停药后2周内回到基线。

临床怎么用

  • VS-505可作为维持性血透高磷血症患者的新型磷结合剂选择,需注意胃肠道不良反应如粪便变色和腹泻。
  • 降磷效果呈剂量依赖性,4.50和6.75 g/日剂量具有临床意义的降磷效果。

局限性

  • 为2期研究,样本量有限,需更大规模3期试验验证。
  • 第二部分为开放标签设计,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VS-505 (AP301), an acacia and ferric oxyhydroxide polymer, is a novel fiber-iron-based phosphate binder. This two-part Phase 2 study evaluated the tolerability, safety and efficacy of oral VS-505 administered three times daily with meals in treating hyperphosphatemia in chronic kidney disease (CKD) patients receiving maintenance hemodialysis (MHD). METHODS: In Part 1, patients received dose-escalated treatment with VS-505 2.25, 4.50 and 9.00 g/day for 2 weeks each, guided by serum phosphorus levels. In Part 2, patients received randomized, open-label, fixed-dosage treatment with VS-505 (1.50, 2.25, 4.50 or 6.75 g/day) or sevelamer carbonate 4.80 g/day for 6 weeks. The primary efficacy endpoint was the change in serum phosphorus. RESULTS: The study enrolled 158 patients (Part 1: 25; Part 2: 133), with 130 exposed to VS-505 in total. VS-505 was well tolerated. The most common adverse events were gastrointestinal disorders, mainly feces discolored (56%) and diarrhea (15%; generally during Weeks 1-2 of treatment). Most gastrointestinal disorders resolved without intervention, and none was serious. In Part 1, serum phosphorus significantly improved (mean change -2.0 mg/dL; 95% confidence interval -2.7, -1.4) after VS-505 dose escalation. In Part 2, serum phosphorus significantly and dose-dependently improved in all VS-505 arms, with clinically meaningful reductions with VS-505 4.50 and 6.75 g/day, and sevelamer carbonate 4.80 g/day [mean change -1.6 (-2.2, -1.0), -1.8 (-2.4, -1.2) and -1.4 (-2.2, -0.5) mg/dL, respectively]. In both parts, serum phosphorus reductions occurred within 1 week of VS-505 initiation, returning to baseline within 2 weeks of VS-505 discontinuation. CONCLUSION: VS-505, a novel phosphate binder, was well tolerated with a manageable safety profile, and effectively and dose-dependently reduced serum phosphorus in CKD patients with hyperphosphatemia receiving MHD. CLINICAL TRIAL REGISTRATION NUMBER: NCT04551300 .

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhuang B, Gan L, Liu B, et al. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Nephrol Dial Transplant. 2024. PMID: 38453435. doi:10.1093/ndt/gfae053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。